A novel method for the detection of Down syndrome with the use of four serum markers.

OBJECTIVE The purpose of this study was to evaluate the use of the Lens culinaris agglutinin-reactive alpha-fetoprotein ratio for the detection of fetal Down syndrome in combination with traditional serum markers. STUDY DESIGN We obtained maternal serum from 530 women with unaffected pregnancies and 31 women who were pregnant with a fetus with Down syndrome at 14 to 20 weeks of gestation. Various combinations of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio, alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol were evaluated by score, without regard for the maternal age-related fetal Down syndrome risk. RESULTS The best combination of serum markers, according to our scoring method, was a combination of all 4 markers. This combination showed a sensitivity of 83.9%, with a 5.1% false-positive rate for Down syndrome. Moreover, in older women, high sensitivity was obtained without increasing the false-positive rate. CONCLUSION The screen using all 4 markers showed high sensitivity in all age groups without increasing the false-positive rate.

[1]  S. Fujimoto,et al.  Lens culinaris agglutinin-reactive α-fetoprotein, an alternative variant to α-fetoprotein in prenatal screening for Down's syndrome , 2001 .

[2]  S. Fujimoto,et al.  Alpha-fetoprotein microheterogeneity: a potential biochemical marker for Down's syndrome. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[3]  L. Cole,et al.  Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies. , 2000, American journal of obstetrics and gynecology.

[4]  L. Cole,et al.  Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome. , 1999, American journal of obstetrics and gynecology.

[5]  L. Cole,et al.  Oligosaccharide variants of hCG‐related molecules: potential screening markers for Downs syndrome , 1997, Prenatal diagnosis.

[6]  Chih-ping Chen,et al.  Maternal serum screening abnormality in a fetus associated with arthrogryposis multiplex congenita and amyoplasia , 1997, Prenatal diagnosis.

[7]  K. Wenstrom,et al.  α-Fetoprotein, free β-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome , 1997 .

[8]  K. Suzumori,et al.  A Retrospective Evaluation of Maternal Serum Screening for the Detection of Fetal Aneuploidy , 1997, Prenatal diagnosis.

[9]  K. Wenstrom,et al.  Second‐trimester maternal serum CA‐125 versus estriol in the multiple‐marker screening test for Down syndrome , 1997, Obstetrics and gynecology.

[10]  L. Boots,et al.  Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old. , 1995, American journal of obstetrics and gynecology.

[11]  R. Osathanondh,et al.  Second‐trimester levels of maternal urinary gonadotropin peptide in down syndrome pregnancy , 1995, Prenatal diagnosis.

[12]  K. Taketa.  Oncofetal alterations of AFP sugar chains , 1995 .

[13]  J. Haddow,et al.  Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening , 1994, The New England journal of medicine.

[14]  K. Wenstrom,et al.  Evaluation of multiple-marker screening for Down syndrome in a statewide population. , 1993, American journal of obstetrics and gynecology.

[15]  G. Prins,et al.  A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. , 1993, American journal of obstetrics and gynecology.

[16]  T. Chard,et al.  Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype , 1993, British journal of obstetrics and gynaecology.

[17]  D. Luthy,et al.  A Prospective Evaluation of a Second-Trimester Screening Test for Fetal Down Syndrome Using Maternal Serum Alpha-Fetoprotein, hCG, and Unconjugated Estriol , 1993, Obstetrics and gynecology.

[18]  J. R. Beekhuis,et al.  Second‐trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome , 1992, Prenatal diagnosis.

[19]  K. Spencer,et al.  Free Beta Human Choriogonadotropin in Down's Syndrome Screening: A Multicentre Study of its Role Compared with other Biochemical Markers , 1992, Annals of clinical biochemistry.

[20]  J. Canick,et al.  Prenatal screening for Down's syndrome with use of maternal serum markers. , 1992, The New England journal of medicine.

[21]  S. Sunderji,et al.  Maternal serum Down syndrome screening: unconjugated estriol is not useful. , 1990, American journal of obstetrics and gynecology.

[22]  J. Canick,et al.  Maternal serum screening for Down's syndrome in early pregnancy. , 1988, BMJ.

[23]  J. Canick,et al.  Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome , 1988, British journal of obstetrics and gynaecology.

[24]  M. Bogart,et al.  Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities , 1987, Prenatal diagnosis.

[25]  Walter E. Johnson,et al.  An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities , 1984 .